Tests elecoglipron against placebo in adults with chronic kidney disease
Tests elecoglipron versus placebo in adults with chronic kidney disease, alongside standard care.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Key facts
- Where
- Bergen, Bodo, Drammen, Foerde, Gjettum, Graalum, Haugesund, Levanger, Loerenskog, Oslo, Skedsmokorset, Skien, Stavanger, Toensberg, Tromsoe, and Trondheim, NorwaySee the 18 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease, with or without type 2 diabetes, who already take a daily ACE inhibitor or ARB. It compares elecoglipron with placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed chronic kidney disease with UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges
- Earlier treatment
- Must be on a stable, maximum tolerated, labeled daily dose of an ACE inhibitor or ARB for ≥4 weeks, at least 28 days before screening
- Biomarker or test result
- UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m²
Main reasons for not taking part
- BMI <23 kg/m² at screening
- History of type 1 diabetes
- HbA1c ≥10% (86 mmol/mol) at screening
- History of pancreatitis, or personal or family history (first degree) of medullary thyroid cancer or MEN2
- Heart attack-type event, major cardiac procedure, stroke or TIA within 3 months before screening
Read by machine on 9 November 2026.
Where in Norway
- Helse Bergen HFBergen, NorwayTaking people
- Nordlandssykehuset HFBodo, NorwayTaking people
- Drammen SykehusDrammen, NorwayTaking people
- Helse Forde HFFoerde, NorwayTaking people
- Vestre Viken HFGjettum, NorwayTaking people
- Sykehuset Oestfold HF KalnesGraalum, NorwayTaking people
- Helse Fonna HFHaugesund, NorwayTaking people
- Helse Nord-Trondelag HFLevanger, NorwayTaking people
- Akershus University HospitalLoerenskog, NorwayTaking people
- Colosseumklinikken Medisinske Senter ASOslo, NorwayTaking people
- Lovisenberg Diakonale Sykehus ASOslo, NorwayTaking people
- Oslo Universitetssykehus HFOslo, NorwayTaking people
- Skedsmo Medisinske Senter ASSkedsmokorset, NorwayTaking people
- Sykehuset Telemark HFSkien, NorwayTaking people
- Helse Stavanger HFStavanger, NorwayTaking people
- Sykehuset I Vestfold HFToensberg, NorwayTaking people
- Universitetssykehuset Nord-Norge HFTromsoe, NorwayTaking people
- St. Olavs hospital HFTrondheim, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07753993EU 2025-523994-41-00
- Record updated
- 9 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Inclusion: Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges; On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Exclusion: Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness; Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening; History of type 1 diabetes mellitus; Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; History/family history (first degree) of medullary thyroid cancer or MEN2; HbA1c ≥10% (86 mmol/mol) at screening; BMI <23 kg/m² at screening.